SUMMARY The pathophysiological role of an increase in circulating vasopressin in sustaining global and regional vasoconstriction in patients with congestive heart failure has not been established, particularly in patients with hyponatraemia. To assess this further, 20 patients with congestive heart failure refractory to digoxin and diuretics were studied before and 60 minutes after the intravenous injection (5ug/kg) of the vascular antagonist of vasopressin [1(P-mercapto-fl, #-cyclopentamethylene-propionic acid), 2-(0-methyl) tyrosine] arginine vasopressin. Ten patients were hyponatraemic (plasma sodium < 135 mmol/l) and 10 were normonatraemic. In both groups of patients the vascular vasopressin antagonist did not alter systemic or pulmonary artery pressures, right atrial pressure, pulmonary capillary wedge pressure, cardiac index, or vascular resistances. Furthermore, there was no change in skin and hepatic blood flow in either group after the injection of the vascular antagonist. Only one patient in the hyponatraemic group showed considerable haemodynamic improvement. He had severe congestive heart failure and a high concentration of plasma vasopressin (51 pmol/l). Plasma renin activity, vasopressin, or catecholamine concentrations were not significantly changed in response to the administration of the vasopressin antagonist in either the hyponatraemic or the normonatraemic groups. Patients with hyponatraemia, however, had higher baseline plasma catecholamine concentrations, heart rate, pulmonary pressure and resistance, and lower hepatic blood flow than patients without hyponatraemia. Plasma vasopressin and plasma renin activity were slightly, though not significantly, higher in the hyponatraemic group. Thus the role of vasopressin in sustaining regional or global vasoconstriction seems limited in patients with congestive heart failure whether or not concomitant hyponatraemia is present. Vasopressin significantly increases the vascular tone only in rare patients with severe congestive heart failure and considerably increased vasopressin concentrations. Patients with hyponatraemia do, however, have raised baseline catecholamine concentrations, heart rate, pulmonary arterial pressure and resistance, and decreased hepatic blood flow.
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Nicod, Biollaz, Waeber, Goy, Polikar, Schlapfer, Schaller, Turini, Nussberger, Hofbauer, Brunner CAD, heart failure secondary to coronary artery disease; IDC, idiopathic dilated cardiomyopathy; LVR, heart failure caused by late valvar replacement. congestive heart failure in several studies.7 -9 In a preliminary report we have shown that vasopressin may have some global vasoconstrictive activity in rare patients presenting with pronounced haemodynamic instability.9 Little is known, however, about the influence of vasopressin on regional redistribution of blood flow in patients with congestive heart failure. Furthermore, the pathophysiological role of vasopressin in patients with hyponatraemia compared with its role in those without hyponatraemia is unknown. Although similar plasma concentrations of vasopressin have been described in patients with congestive heart failure with and without hyponatraemia, vasopressin concentrations are inappropriately high in the context of plasma sodium concentration, especially in patients with hyponatraemia.
We have analysed the global and the regional haemodynamic variables before and after the injection of a vascular antagonist of vasopressin in patients with congestive heart failure and we have compared the results obtained in patients with hyponatraemia with those obtained in patients without hyponatraemia.
Patients and methods

PATIENT SELECTION
Twenty patients were studied (17 men and 3 women, aged 19 to 81) with New York Heart Association class III and IV congestive heart failure refractory to conventional treatment with digoxin and diuretics. Patients were divided into two groups according to plasma sodium concentration. One group (10 patients) was hyponatraemic (plasma sodium < 135 mmol/I (mean (SEM) 129 (2) mmol/1) and the other group (10 patients) was normonatraemic (plasma sodium 137 (1) mmol/l). Table 1 shows their clinical characteristics and their medications. At the time of the study all patients had been maintained on stable doses of digoxin and diuretics for at least two weeks. They had been on a daily diet of < 3 g sodium for at least three days. The aetiology of congestive heart failure was idiopathic dilated cardiomyopathy in 14 patients, coronary artery disease in five patients, and late valvar replacement for aortic insufficiency in one patient. All Brunner (synthesised by Ciba Geigy, Basel, Switzerland)."7
On the day of the study it was dissolved in 0 9% saline solution to a final concentration of 100 Mg/ml. This solution was passed through a Milex CS filter (Milipor, Molsheim, France) before intravenous injection. Plasma renin activity and vasopressin concentrations tended to be higher, but not significantly, in the group with hyponatraemia. Concentrations of adrenaline (5 95 (2 46) Figure 2 shows the responses of systemic arterial pressure, systemic arterial resistance, pulmonary capillary wedge pressure, cardiac index, and heart rate to the vasopressin antagonist. None of In previous studies no significant differences in vasopressin concentrations were reported between patients with congestive heart failure with and without hyponatraemia.7 8 We too found no differences in plasma concentrations nor in global or regional vasoconstrictive activity of vasopressin between these two groups of patients.
PROTOCOL
In our study plasma renin activity was slightly but not significantly higher in patients with congestive heart failure and hyponatraemia than in those without hyponatraemia. These findings, together with the significant increase in plasma renin activity seen hyponatraemia had raised catecholamine concentrations, heart rate, pulmonary arterial pressure and resistance, and decreased hepatic blood flow, but there were no differences in the other haemodynamic variables measured. This pattern resembles results reported by Lilly et al in patients off diuretics,27 and probably reflects a more severe congestive heart failure in the hyponatraemic group. In the hyponatraemic group catecholamines may maintain global haemodynamic variables at values similar to the normonatraemic group by using the chronotropic and inotropic reserve of the heart.
In conclusion, plasma vasopressin seems to play a very limited role in sustaining global and regional vasoconstriction in patients with congestive heart failure with or without hyponatraemia. Hyponatraemia was not consistently associated with high plasma vasopressin concentrations nor with an increased haemodynamic response to the vasopressin antagonist. Hyponatraemia was, however, accompanied by increased catecholamine levels, heart rate, pulmonary arterial pressure and resistance, and decreased hepatic blood flow. This suggests that continuing hyponatraemia despite treatment with diuretics and digoxin is a marker for severe congestive heart failure.
